Research Unit on Reproductive and Developmental Biology, Pediatric Research Center, Hôpital Sainte-Justine and Université de Montréal, Montréal, Québec, Canada H3T 1C5.
J Neuroendocrinol. 1990 Dec 1;2(6):833-8. doi: 10.1111/j.1365-2826.1990.tb00648.x.
Abstract The secretion of prolactin by the pituitary gland is under a tonic inhibitory control exerted by tubero-infundibular dopamine. Recently, it has been suggested that dopamine may exert its action by inhibiting production of inositol phosphates and mobilization of intracellular Ca(2+). To study the effects of dopamine on the production of inositol phosphates and prolactin release, we have utilized an estrone-induced, dopamine-sensitive rat pituitary adenoma and two transplantable and dopamine-resistant rat pituitary tumors, 7315a and MtTW15. Purified cells, obtained from the three tissues, were incubated for 30 min in media with drugs (thyrotropin-releasing hormone or angiotensin II) stimulating inositol phosphates and prolactin release, in the presence or the absence of dopamine. Basal production of inositol phosphates and prolactin release by adenomatous lactotrophs were inhibited by dopamine. Thyrotropin-releasing hormone and angiotensin II stimulated inositol phosphates by adenomatous and 7315a cells. This effect was antagonized by dopamine in adenomatous cells. Prolactin release by adenomatous cells only was stimulated by thyrotropin-releasing hormone and angiotensin II. This stimulation was inhibited by dopamine. The results show differences, in the mechanisms of regulation of prolactin release, between adenoma and transplantable pituitary tumors as well as between the two tumors themselves. These differences may be responsible, in part, for the resistance of the two transplantable pituitary tumors to the inhibitory effects of dopamine on prolactin release and tumor size. Our results obtained both with adenoma and tumoral cells also suggest that inositol phosphates probably intervene only in the late phases of dopamine inhibition of prolactin release and only in the presence of a normal Ca(2+) signaling system.
摘要 垂体前叶分泌催乳素受到来自结节漏斗部的多巴胺的紧张性抑制控制。最近,人们提出多巴胺可能通过抑制肌醇磷酸的产生和细胞内 Ca(2+)的动员来发挥作用。为了研究多巴胺对肌醇磷酸产生和催乳素释放的影响,我们利用了雌酮诱导的多巴胺敏感的大鼠垂体腺瘤以及两种可移植的且对多巴胺有抗性的大鼠垂体肿瘤 7315a 和 MtTW15。从这三种组织中获得的纯化细胞,在含有药物(促甲状腺素释放激素或血管紧张素 II)的培养基中孵育 30 分钟,这些药物刺激肌醇磷酸和催乳素的释放,同时存在或不存在多巴胺。腺瘤性催乳细胞的基础肌醇磷酸产生和催乳素释放受到多巴胺的抑制。促甲状腺素释放激素和血管紧张素 II 刺激腺瘤和 7315a 细胞的肌醇磷酸。这种作用在腺瘤细胞中被多巴胺拮抗。促甲状腺素释放激素和血管紧张素 II 仅刺激腺瘤细胞的催乳素释放。这种刺激被多巴胺抑制。结果表明,在催乳素释放的调节机制方面,腺瘤与可移植的垂体肿瘤之间以及这两种肿瘤本身之间存在差异。这些差异可能部分解释了两种可移植的垂体肿瘤对多巴胺抑制催乳素释放和肿瘤大小的作用的抗性。我们从腺瘤和肿瘤细胞中获得的结果还表明,肌醇磷酸可能仅在多巴胺抑制催乳素释放的晚期阶段以及在正常的 Ca(2+)信号转导系统存在的情况下发挥作用。